Raphael Pharmaceutical Inc. (RAPH) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US27785B2088

Price
1.51 USD
Market cap
30.47 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Raphael Pharmaceutical Inc. financials

Fiscal year2025
Operating income-1.25 m USD
EBIT-1.28 m USD
Net income-1.28 m USD
Diluted EPS – continuing operations0.07 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Raphael Pharmaceutical Inc.

Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.